However, the changes in Fibulin 3, Tinag-like 1, and Elastin were more significant in SSc-ILD (27), and drugs targeting these proteins may be considered SSC-ILD-specific therapies. This evidence concerns the gene TINAGL1 and interstitial lung disease.